Abbott halts study on early-stage Alzheimer's drug

Abbott confirmed it stopped study of an early-stage compound for Alzheimer's. The drug, which was in early human clinical trials, wasn't working. The decision to halt the study of ABT-089 had nothing to do with safety issues, N. Chicago-based medical product company said. "It was well tolerated, & there were no new safety signals identified. We continue to evaluate a number of early stage compounds in Alzheimers," Abbott said. The news on the decision to halt the study was disclosed in Vienna by a researcher involved in the study. The update on Abbott drug was presented at the Int